Histamine-2 Receptor Antagonist Use and Incident Dementia in an Older Cohort

OBJECTIVES: To examine whether histamine‐2 receptor antagonist medications (H2RAs) are associated with a lower incidence of all‐cause dementia or Alzheimer's disease (AD), as some studies have suggested. DESIGN: Prospective population‐based cohort SETTING: Group Health, an integrated health mai...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Geriatrics Society (JAGS) 2011-02, Vol.59 (2), p.251-257
Main Authors: Gray, Shelly L., Walker, Rod, Dublin, Sascha, Haneuse, Sebastien, Crane, Paul K., Breitner, John C. S., Bowen, James, McCormick, Wayne, Larson, Eric B.
Format: Article
Language:English
Subjects:
Adult and adolescent clinical studies
Aged
Aged, 80 and over
Alzheimer's disease
Antacids
Biological and medical sciences
cohort study
Data processing
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Dementia
Dementia - drug therapy
Dementia - epidemiology
Dementia disorders
Dose-Response Relationship, Drug
Drugs
Female
Follow-Up Studies
General aspects
Geriatrics
Histamine H2 Antagonists - administration & dosage
Histamine H2 Antagonists - therapeutic use
Histamine H2 receptors
histamine-2 receptor antagonist
Humans
Incidence
Light effects
Male
Medical sciences
Neurodegenerative diseases
Neurology
Older people
Organic mental disorders. Neuropsychology
pharmacoepidemiology
Prescription drugs
Prospective Studies
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Recruitment
Risk Factors
Time Factors
Washington - epidemiology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVES: To examine whether histamine‐2 receptor antagonist medications (H2RAs) are associated with a lower incidence of all‐cause dementia or Alzheimer's disease (AD), as some studies have suggested. DESIGN: Prospective population‐based cohort SETTING: Group Health, an integrated health maintenance organization, Seattle, Washington. PARTICIPANTS: Two thousand nine hundred twenty‐three participants aged 65 and older without dementia at baseline, with initial recruitment between 1994 and 1996. MEASUREMENTS: Follow‐up occurred every 2 years to identify incident dementia and AD using standard criteria. Exposure to H2RAs was determined based on automated pharmacy data. Three aspects of exposure (time‐varying) were examined based on standard daily dose (SDD): cumulative use, intensity of use (highest SDD in any prior 2‐year window), and cumulative use stratified according to recency (1–3 years vs >3 years before). RESULTS: Over a mean follow‐up of 6.7 years, 585 subjects developed dementia (453 developed AD). Total cumulative exposure was not associated with dementia (P=.35; omnibus test) or AD (P=.23). The adjusted hazard ratios for the highest exposure category (>1,080 SDDs) compared with light or no use were 1.28 (95% confidence interval (CI)=0.95–1.72) for dementia and 1.41 (95% CI=1.00–1.97) for AD. Intensity of use was not associated with dementia (P=.39) or AD (P=.63). Examining exposure according to recent and distant cumulative use also showed no association with dementia (P=.11) or AD (P=.30). CONCLUSION: No association was found between H2RA use and risk of all‐cause dementia or AD using more‐detailed and ‐extensive information about past H2RA use than any prior study.
ISSN:0002-8614
1532-5415
DOI:10.1111/j.1532-5415.2010.03275.x